Reducing the Impact of Rheumatic Heart Disease across the Life Span: The Impact Program

本申请寻求为D43培训基金提供资金，以支持世界首例风湿性心脏病 (RHD)乌干达的研究培训计划。在全球范围内，风湿性心脏病的预防几乎没有创新， 早在1900年中期就发现和管理了S。此外，大多数证据都指导着 目前的做法产生于高收入国家，可能不会直接转化为当代的 低收入和中等收入国家的疾病负担。影响指导型研究-培训 计划将利用现有资源和来自长达十年的RHD研究的正在进行的RHD临床试验 Makerere大学、乌干达心脏研究所(UHI)、辛辛那提之间的培训合作 儿童医院医疗中心(CCHMC)和国立儿童医院(CNH)建设能力 在负担最重的地方解决风湿性心脏病。我们的首要目标是装备和培育新兴企业 乌干达的研究领导者和专业学者将就以下问题产生高质量的当代证据 并在非洲大陆建立一个经久不衰的研究培训中心， 将在一代人的时间内迅速推进消除这种疾病的进展；大胆但可以实现的 进球。该应用程序将为实现以下目标所需的培训和研究活动提供关键支持 这个愿景。该项目将由医学教授Nelson Sewankambo博士领导 Makerere大学医学院前院长，曾领导多个NIH和非NIH 乌干达和撒哈拉以南非洲的研究能力建设赠款。共同执导这个节目的是联合- 乌干达风湿性心脏病研究合作中心(RRCU)主任Emmy Okello博士 和安德里亚·比顿(CCHMC)。长期硕士、博士学位培训与职业发展 将提供奖学金级别的课程，主要课程将在乌干达的MakCHS进行。CNH将提供 在美国举办电子学习研讨会和面对面沉浸式体验，以加强临床试验能力 并提高受训者对性别平等和性别--以及卫生研究中的性别考虑--的知识。 此外，征聘将以区域中心的受训人员为目标，以建设国家人力资源开发能力，并 确保我们的实习生中至少有50%是女性。短期培训、研讨会、网络研讨会和讲习班 将向学位和非学位学员提供培训，以进一步加强机构和国家RHD- 研究能力和寻找有前途的学位课程候选人。一个督导委员会和 培训咨询委员会(TAC)由对我们的目标具有专业知识的领先研究人员组成 两者都将向Impact董事提供专家建议，以确保学员和整体的成功 计划通过产生高质量和与当地相关的研究。这一成功将转化为改进 乌干达和该地区风湿性心脏病护理的指导方针和政策，培养下一代优秀的 非洲研究人员将致力于风湿性心脏病的预防、早期发现和管理。

This application seeks funding for a D43 training grant to support a world-first rheumatic heart disease (RHD) research training program in Uganda. There has been little innovation globally in RHD prevention, early detection, and management since the mid-1900’s. Additionally, the majority of evidence guiding current practice was generated in high-income countries and may not translate directly to the contemporary burden of disease in low- and middle-income countries (LMICs). The Impact Mentored Research-Training Program will leverage existing resources and ongoing RHD clinical trials from a decade-long RHD research and training collaboration between Makerere University, the Uganda Heart Institute (UHI), Cincinnati Children’s Hospital Medical Centre (CCHMC) and Children’s National Hospital (CNH) to build capacity to tackle RHD where the burden is the highest. Our overarching objective is to equip and nurture emerging research leaders and professional scholars in Uganda to generate high-quality contemporary evidence on RHD across the lifespan and to create an enduring research training center on the African continent that will rapidly advance progress towards the elimination of the disease in a generation; a bold, but achievable goal. This application will provide critical support for the training, and research activities needed to realize this vision. The program will be led by Dr. Nelson Sewankambo, a Professor of Medicine and Former Dean of the Makerere University School of medicine, who has led several NIH and non-NIH research capacity building grants in Uganda and sub-Saharan Africa. Co-directing this program are the co- Directors of the Rheumatic Heart Disease Research Collaborative in Uganda (RRCU), Drs. Emmy Okello (UHI) and Andrea Beaton (CCHMC). Long-term degree training at Master’s, PhD and Career development fellowship levels will be offered, with primary coursework to occur in Uganda at MakCHS. CNH will provide both e-learning seminar and in-person immersive experience in the US to strengthen clinical trials capacity and improve trainee’s knowledge of gender parity and sex- and gender considerations in health research. Additionally, recruitment will target trainees from the regional centers to build National RHD capacity and ensure at least 50% of our trainees are women. Short-term trainings, seminars, webinars and workshops will be offered to degree and non-degree trainees to further strengthen institutional and national RHD- research capacity and to identify promising candidates for degree programs. A Steering Committee and the Training Advisory Committee (TAC) comprised of leading researchers with expertise in our objectives will both offer expert advice to the Impact Directors to ensure success of the trainees and the overall program by producing high-quality and locally relevant research. This success will translate into improving guidelines and policies for RHD care in Uganda and the region, training the next generation of excellent African researchers to address RHD prevention, early detection, and management.